EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Upfront menin-inhibitor resistance in multiply pretreated leukemias

Leila Mahdavi, Fatemeh Alikarami, Haley Goodrow, Alexandra Lenard, Simone S Riedel, Clara Libbrecht, Isabel Bowser, Sarah K Tasian, Catherine D Falkenstein, Bryan Manning, Sarah Skuli, Martin P Carroll und 7 weitere

Experimental Hematology · 2026-01 · 153 · 105268

DOI: 10.1016/j.exphem.2025.105268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Hematology, 2026-01. Verfasst von Leila Mahdavi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins, Drug Resistance, Neoplasm, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Leukemia and Lymphoma Society, Les 111 des Arts, Emerson Collective.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene ProteinsDrug Resistance, NeoplasmLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaHumansMyeloid-Lymphoid Leukemia ProteinAnimalsMiceHistone-Lysine N-MethyltransferaseFemaleMaleInfantXenograft Model Antitumor Assays

Substanzen

Proto-Oncogene ProteinsMEN1 protein, humanMyeloid-Lymphoid Leukemia ProteinKMT2A protein, humanHistone-Lysine N-Methyltransferase

Autor:innen und Institutionen

  • Division of Pediatric Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Division of Pediatric Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania and Abramson Cancer Center, Philad…
  • Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Department of Pathology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Syndax Pharmaceuticals, Inc. Waltham, Pennsylvania.

Förderung

  • Leukemia and Lymphoma Society
  • Les 111 des Arts
  • Emerson Collective
  • Children's Hospital of Philadelphia

Zitieren

APA

Mahdavi, L., Alikarami, F., Goodrow, H., Lenard, A., Riedel, S. S., Libbrecht, C., Bowser, I., Tasian, S. K., Falkenstein, C. D., Manning, B., Skuli, S., Carroll, M. P., Wertheim, G., Cai, S. F., McGeehan, G., Yu, S., Shi, J., Xie, H. M., & Bernt, K. M. (2026). Upfront menin-inhibitor resistance in multiply pretreated leukemias. Experimental Hematology. https://doi.org/10.1016/j.exphem.2025.105268

Vancouver

Mahdavi L, Alikarami F, Goodrow H, Lenard A, Riedel SS, Libbrecht C, et al. Upfront menin-inhibitor resistance in multiply pretreated leukemias. Experimental Hematology. 2026. doi:10.1016/j.exphem.2025.105268

BibTeX
@article{Mahdavi2026,
  author = {Mahdavi, Leila and Alikarami, Fatemeh and Goodrow, Haley and Lenard, Alexandra and Riedel, Simone S and Libbrecht, Clara and Bowser, Isabel and Tasian, Sarah K and Falkenstein, Catherine D and Manning, Bryan and Skuli, Sarah and Carroll, Martin P and Wertheim, Gerald and Cai, Sheng F and McGeehan, Gerard and Yu, Sixiang and Shi, Junwei and Xie, Hongbo M and Bernt, Kathrin M},
  title = {Upfront menin-inhibitor resistance in multiply pretreated leukemias},
  journal = {Experimental Hematology},
  year = {2026},
  doi = {10.1016/j.exphem.2025.105268}
}
Kostenlos starten →